In an effort to re-evaluate the selectivity profile of CDC for LOXs, Pergola et al. identified CDC as an ALOX5-specific antagonist with an IC50 value in the low nanomolar range (9–25 nM) measured in cell-free assays.251 Zileuton, another widely used ALOX5-selective inhibitor, was the first FDA-approved orally administered drug for treating asthma. The gene discussed is ALOX5; the disease is asthma.